Spots Global Cancer Trial Database for carcinoid
Every month we try and update this database with for carcinoid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Natural History of Familial Carcinoid Tumor | NCT00646022 | Carcinoid | [18F]-DOPA | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00780663 | Neuroendocrine ... Carcinoid Tumor | Quarfloxin | 18 Years - | Cylene Pharmaceuticals | |
| Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples | NCT01216267 | Neuroendocrine ... | Lansoprazole lansoprazole | 18 Years - 70 Years | University of Western Ontario, Canada | |
| Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease | NCT05064514 | Tricuspid Regur... Tricuspid Valve... Carcinoid Syndr... Carcinoid Heart... | Transcatheter T... | 18 Years - | Queen Mary University of London | |
| Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease | NCT05064514 | Tricuspid Regur... Tricuspid Valve... Carcinoid Syndr... Carcinoid Heart... | Transcatheter T... | 18 Years - | Queen Mary University of London | |
| Study of Panitumumab in the Treatment of Carcinoid Syndrome | NCT01172717 | Carcinoid Syndr... | Panitumumab | 18 Years - | Boston Medical Center | |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | NCT02549937 | Tumors | surufatinib | 18 Years - | Hutchmed | |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00388063 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| RegisterNET - A Registry for Neuroendocrine Tumors in the USA | NCT02270567 | Neuroendocrine ... Carcinoid Neuroendocrine ... | NETest | 21 Years - | Wren Laboratories LLC | |
| Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00780663 | Neuroendocrine ... Carcinoid Tumor | Quarfloxin | 18 Years - | Cylene Pharmaceuticals | |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver | NCT00986661 | Cancer Metastat... Hepatocellular ... Metastatic Mela... Metastatic Ocul... Metastatic Uvea... Metastatic Lung... Metastatic Colo... Metastatic Colo... Metastatic Brea... Metastatic Panc... | PV-10 (10% rose... | 18 Years - | Provectus Pharmaceuticals | |
| Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors | NCT00672269 | Carcinoid Neuro... | 12 Years - | Rutgers University | ||
| RegisterNET - A Registry for Neuroendocrine Tumors in the USA | NCT02270567 | Neuroendocrine ... Carcinoid Neuroendocrine ... | NETest | 21 Years - | Wren Laboratories LLC | |
| Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples | NCT01216267 | Neuroendocrine ... | Lansoprazole lansoprazole | 18 Years - 70 Years | University of Western Ontario, Canada | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | NCT02859064 | Neuroendocrine ... Gastrointestina... Carcinoid Tumor... | Lanreotide Y-90 microspher... | 18 Years - | SCRI Development Innovations, LLC | |
| Natural History of Familial Carcinoid Tumor | NCT00646022 | Carcinoid | [18F]-DOPA | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | NCT05477576 | GEP-NET Gastroenteropan... Gastroenteropan... Neuroendocrine ... Carcinoid Carcinoid Tumor Pancreatic NET | RYZ101 Everolimus 10 m... Sunitinib 37.5 ... Octreotide LAR ... Lanreotide 120M... | 18 Years - | RayzeBio, Inc. | |
| RAD001 and Erlotinib in Patients With Neuroendocrine Tumors | NCT00843531 | Neuroendocrine ... | RAD001 erlotinib | 18 Years - | University of California, San Francisco | |
| An Investigation of Small Intestinal Carcinoid Carcinoma in Families | NCT00662168 | Carcinoid Carci... | 12 Years - | Rutgers University | ||
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00388063 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion | NCT00227136 | Carcinoid Tumor... Neuroendocrine ... | 5-Hydroxy-Trypt... | 18 Years - | Western University, Canada | |
| Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor | NCT00412061 | Carcinoid Tumor Malignant Carci... | Octreotide Placebo Everolimus | 18 Years - | Novartis | |
| A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers | NCT02132468 | Neuroendocrine ... | fosbretabulin t... | 18 Years - | Mateon Therapeutics | |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid | NCT00339131 | Pheochromocytom... Paraganglioma Carcinoid | Ultratrace iobe... | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00388063 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer | NCT01396382 | Neuroendocrine ... | 68Ga-DOTATATE P... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Natural History of Familial Carcinoid Tumor | NCT00646022 | Carcinoid | [18F]-DOPA | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | NCT02859064 | Neuroendocrine ... Gastrointestina... Carcinoid Tumor... | Lanreotide Y-90 microspher... | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study | NCT01271959 | Solid Organ Tum... | 18 Years - | Precision Therapeutics | ||
| Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | NCT01165658 | Non-small Cell ... Small Cell Lung... Carcinoid Thymic Cancer Lung Cancer | Proton Therapy | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | NCT00690430 | Symptomatic Ref... | Pasireotide Octreotide | 18 Years - | Novartis | |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples | NCT01216267 | Neuroendocrine ... | Lansoprazole lansoprazole | 18 Years - 70 Years | University of Western Ontario, Canada | |
| Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | NCT00690430 | Symptomatic Ref... | Pasireotide Octreotide | 18 Years - | Novartis | |
| RegisterNET - A Registry for Neuroendocrine Tumors in the USA | NCT02270567 | Neuroendocrine ... Carcinoid Neuroendocrine ... | NETest | 21 Years - | Wren Laboratories LLC | |
| Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | NCT01165658 | Non-small Cell ... Small Cell Lung... Carcinoid Thymic Cancer Lung Cancer | Proton Therapy | 18 Years - | M.D. Anderson Cancer Center | |
| Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion | NCT00227136 | Carcinoid Tumor... Neuroendocrine ... | 5-Hydroxy-Trypt... | 18 Years - | Western University, Canada | |
| Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers | NCT03623984 | Neuroendocrine ... Carcinoid | Gallium Dotatat... | 19 Years - 100 Years | University of Alabama at Birmingham | |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver | NCT00986661 | Cancer Metastat... Hepatocellular ... Metastatic Mela... Metastatic Ocul... Metastatic Uvea... Metastatic Lung... Metastatic Colo... Metastatic Colo... Metastatic Brea... Metastatic Panc... | PV-10 (10% rose... | 18 Years - | Provectus Pharmaceuticals | |
| Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor | NCT00412061 | Carcinoid Tumor Malignant Carci... | Octreotide Placebo Everolimus | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
